Antengene Corp. Ltd. operates as a clinical-stage Asia-Pacific biopharmaceutical company. It focuses on the discovery, development, manufacturing and commercialization of therapeutics for the treatment of hematologic malignancies and solid tumors. It operates in mainland China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia countries. The company was founded by Jian Ming Mei on August 28, 2018, and is headquartered in Shanghai, China.